中文
  • Home
  • About Us
  • Practice
  • Professionals
  • News
  • Publication
  • Join Us
  • Contact Us
  • Home
  • About Us
  • Practice
  • Professionals
  • News
  • Publication
  • Join Us
  • Contact Us
  • NEWSLETTER
  • UPDATES & VIEW
  • CASE STUDY
  • REPRESENTATIVES
2023/05/16 ZY Partners By
The Initiative of the CNIPA to regulate bad faith filings showing from the Draft Amendment to the PRC Trademark Law
Li Xiaohong and Han Yajie of ZY Partners detail the proposals for the emphasize use requirement, the “Preclusion of Repeated Registration”, and penalties for malicious trademark squatting, among others, that, if implemented, could combat bad faith filings.

2022/05/31 By Chen, Fei and Jiao, Yuxin, ZY Partners By
Demystifying China’s Intellectual Property Jurisdiction: Does the New Supreme Court Jurisdiction Rule Present a “Mere-glance” Guideline?
The 3rd. Division of the PRC Supreme Court announced a new set of rules on 21 April 2022 concerning Provisions on Jurisdiction of Intellectual Property Civil and Administrative Cases of First Instance(”Jurisdiction Rules” ).[3] The new Jurisdiction Rules represents a new round of endeavor of the PRC Supreme Court to cope with the complications arising from the chronicle problem of contradictory and often opaque rules of intellectual property jurisdiction. Said jurisdictional rules of the Supreme Court is to take effective on 1 May 2022.

2022/04/20 Chen Fei, Associate Attorney at ZY Partners By
Should Perjury Bow Low to King Clause in the PRC Courts? -- the PRC Supreme Court Hum and Hawed in Guiding Case No. 82.
Could one be benefited from perjury in the PRC courts? Do not be shocked if you happen to find out that the answer is an unbelievable “yes”. Though perjury is a crime punishable by the PRC Criminal Law, however, perjury under the criminal penal code is limited to curb conduct of perjury relevant only to the criminal procedure, leaving the gate for perjury wide open and unpunishable in the PRC civil proceedings

2022/03/03 Chen Fei, ZY Partners By
Antitrust Warning from the Chinese Supreme Court on Settlement between Pharma Patentee and Generic Challenger in Patent Invalidation Proceedings

网站备案许可号:京ICP17040213

    

京公网安备 11010502033765号